摘要
目的比较美托洛尔和卡维地洛两种β受体阻滞剂治疗慢性心力衰竭的临床疗效。方法随机将心内科收治的92例慢性心力衰竭患者分为美托洛尔组和卡维地洛组,各46例。常规治疗基础上,美托洛尔组给予美托洛尔治疗,卡维地洛组给予卡维地洛治疗,疗程12周。评价两组患者治疗前后的心功能分级,并分别使用酶联免疫法和超声心动图测定其治疗前后的血浆肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)水平,左心室收缩末期内径(LVESd)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDd)。结果两组患者治疗后,其心功能分级、细胞因子、心脏重塑逆转等均有显著改善,但卡维地洛的治疗效果明显优于美托洛尔,差异有统计学意义(P<0.05)。结论美托洛尔与卡维地洛治疗心力衰竭均有效,与美托洛尔相比,卡维地洛的治疗效果更显著,适合临床推广使用。
Objective To investigate and compare the clinical efficacy of metoprolol and carvedilol in chronic heart failure. Methods All 96 patients with chronic heart failure patients admitted to hospital of Cardiology treatment were divided into metoprolol group and carvedilol group, 48 cases in each group. Classification of cardiac function were evaluated before and after treatment, respectively, using enzyme-linked immunosorbent assay and measured by echocardiography before and after treatment of TNF-ct, IL-6 plasma content, left ventricular end systolic diameter （LVESd）, left ventricular ejection fraction （LVEF）, left ventricular end diastolic diameter （LVEDd）. Results After treatment, cardiac function classification, cytokines, and cardiac remodeling reversal and other significant improved in two groups, but the treatment effect of carvedilol group is superior to metoprolol group, the difference was statistically significant （P 〈0.05）. Conclusion Metoprolol and carvedilol are valid in the treatment of heart failure,compared with metoprolol, carvedilol treatment is more suitable for clinical use.
出处
《当代医学》
2013年第3期106-107,共2页
Contemporary Medicine
